Acetylcysteine injection - Cumberland Pharmaceuticals

Drug Profile

Acetylcysteine injection - Cumberland Pharmaceuticals

Alternative Names: N-acetylcysteine (NAC) injection - Cumberland Pharmaceuticals; Acetadote; Intravenous NAC - Cumberland Pharmaceuticals

Latest Information Update: 07 Feb 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Cumberland Pharmaceuticals
  • Developer Al-Nabil; Cumberland Pharmaceuticals; GerminMED; Harbin Gloria Pharmaceuticals
  • Class Antibronchitics; Expectorants; Reducing agents; Small molecules; Sulfur amino acids
  • Mechanism of Action Antioxidants; Free radical inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Poisoning
  • New Molecular Entity No

Highest Development Phases

  • Marketed Poisoning
  • Preregistration Liver failure
  • Discontinued Kidney disorders

Most Recent Events

  • 30 Jan 2017 Cumberland Pharmaceuticals won the patent litigation in the US Court of Appeals for the Federal Circuit, filed against Mylan, for a patent validity case associated with Acetadote® product, in USA
  • 15 Mar 2016 Biomarkers information updated
  • 24 Mar 2014 Discontinued - Phase-II/III for Kidney disorders (prevention) in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top